Related Experiment Videos
A protocol to inject ocular drug implants into mouse eyes
Cheng-Hui Lin1, Young Joo Sun2, Soo Hyeon Lee2
1Byers Eye Institute, Department of Ophthalmology, Stanford University, Stanford, CA 94304, USA.
STAR Protocols
|February 10, 2022
Summary
A new Mouse Implant Intravitreal Injection (MI3) protocol enables minimally invasive delivery of ocular drug implants (ODIs) in mice. This cost-effective method overcomes limitations in preclinical testing for new eye disease treatments.
Area of Science:
- Ophthalmology
- Biomedical Engineering
- Drug Delivery Systems
Background:
- Ocular drug implants (ODIs) offer therapeutic advantages for various eye conditions.
- Developing and testing ODIs is hindered by the lack of effective delivery methods in small-eyed animal models.
- Preclinical evaluation of ODIs requires reliable methods for intravitreal administration.
Purpose of the Study:
- To introduce a novel, minimally invasive protocol for delivering ocular drug implants into the mouse vitreous.
- To address the technical limitations in applying ODIs to small-eyed model organisms.
- To facilitate preclinical assessment of ODI efficacy, toxicity, and pharmacokinetics.
Main Methods:
- Development of the Mouse Implant Intravitreal Injection (MI3) protocol.
- Implementation of two distinct surgical approaches: air-pressure and plunger-based delivery.
- Adaptation of micro-scaled implants for delivery into milli-scaled rodent eyes.
Main Results:
- MI3 provides a cost-effective and minimally invasive method for ODI delivery.
- The protocol successfully delivers micro-implants into the mouse vitreous cavity.
- MI3 expands the available preclinical platforms for ocular drug development.
Conclusions:
- The MI3 protocol is a significant advancement for preclinical ocular drug implant research.
- This method enables more robust evaluation of ODIs in a relevant animal model.
- MI3 facilitates the development and optimization of novel treatments for ocular diseases.